“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

Monotherapy with SGLT2 inhibitors or GLP-1RAs is associated ... Please see the original reference for a full list of authors’ disclosures.

[83] List et al. (2009) T2DM drug-naive patients ... co-transporters located at the brush border of tubular cells (SGLT2 and SGLT1) and the GLUTs facilitated diffusion glucose transporters ...

“Our study suggests that SGLT2 inhibitors may provide benefit in ... Please see the original reference for a full list of disclosures. Bonnesen K, Heide-Jørgensen U, Christensen DH, et al.

No randomized clinical trials have directly compared empagliflozin with dapagliflozin for type 2 diabetes, so investigators conducted a large comparative effectiveness study examining kidney outcomes.

Sotagliflozin is an SGLT-2 inhibitor approved to treat type 2 diabetes ... NY), with 16 more sites anticipated to begin recruiting soon throughout the U.S. and Canada. See a full list of ...

SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...

sodium-glucose transporter 2 (SGLT2) inhibitors — these reduce the amount of glucose reabsorbed by the kidneys, meaning that it is excreted in the urine. A meta-analysis, published in the ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SGLT2 inhibitors were more cardioprotective in older people, but reduced HbA1c less with age. GLP-1 receptor agonists ...